chevron_leftBack
As of 24 April 2025, Jafron Biomedical Co.,Ltd. has a market cap of $2.35B USD, ranking #4810 globally and #998 in China. It ranks #430 in the Healthcare sector, and #43 in the Medical Devices industry.
Key Stats
Market Cap
$2.35BUSD
17.12B CNY
Enterprise Value
$2.19BUSD
15.94B CNY
Revenue (TTM)
$340.44MUSD
2.48B CNY
EBITDA (TTM)
$139.01MUSD
1.01B CNY
Net Income (TTM)
$99.38MUSD
724.21M CNY
EBITDA Margin
41%
Profit Margin
29%
PE Ratio
23.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Fan Dong
open_in_new
Employees
2,797
Founded
1989
Website
jafroninternational.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.4% | -9.3% | -15% | -19% | -31% | -3% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
300529
健帆生物科技集团股份有限公司 Class A
ISIN: CNE100002995
Shares Out.:
Shares Outstanding:
762.54M1
Shares Float:
568.808M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
22.11 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Jafron Biomedical Co.,Ltd.
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis concentrate, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles, as well as syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
